CD8A and melanoma: In NOD-scid IL-2Rγnull mice injected with human melanoma tumor cells, nemvaleukin alfa SC induced significantly higher counts of CD8-positive T cells and NK cells and lower counts of Tregs within their spleens compared to rhIL-2 treatment; evaluation of the implanted melanoma tumors revealed that nemvaleukin alfa SC increased the percentages of intratumoral T cells and CD8-positive T cells and reduced the percentages of intratumoral Tregs compared to the vehicle.